ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ)
$56.93 0.72 (1.2809%)
Analysed ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ) News Sources
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
04-09-2026
yahoo.com
Royalty Pharma to present at upcoming investor conferences
09-09-2026
yahoo.com
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?
10-09-2026
yahoo.com
Blood Cancer United Announces $7.5 Million Gift From Royalty Pharma to Expand Therapy Acceleration Program
15-09-2026
yahoo.com
Royalty Pharma (RPRX) Could Be 10% Undervalued As Conference Spotlight Returns
23-09-2026
yahoo.com
Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run
23-09-2026
yahoo.com
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
25-09-2026
marketbeat.com
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
01-10-2026
fool.com
Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again
08-10-2026
yahoo.com
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
09-10-2026
yahoo.com
What is the current price of ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ)?
The current price of ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ) is $56.93.
ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ) since the previous trading day is $0.72.
ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ) since the previous trading day is 1.2809%.
What is the most recent average sentiment score for ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ)?
The most recent average sentiment score for ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ) is 69 out of 100.
What is the most recent average sentiment for ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ)?
The most recent sentiment for ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ) is .
SEC-8K** Filing Available For ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.